Oral semaglutide 25 mg (Wegovy; Novo Nordisk) reached a peak weekly initiation rate of 4.56 per 10,000 eligible US adults within 10 weeks of its December 22, 2025 FDA approval for weight management, according to a JAMA Network Open research letter — a signal that oral GLP-1 receptor agonists are rapidly reshaping obesity treatment demand and the peptide supply chain that serves it. The retrospective analysis of 47,894,786 adults eligible for obesity medications found that oral semaglutide briefly overtook injectable semaglutide in weekly initiations, though tirzepatide maintained the highest rate throughout the study period.
What the Epic Cosmos Data Show
The study, led by researchers at the University of Pennsylvania, used deidentified electronic health record data from Epic Cosmos, covering more than 300 million patient records from over 2,000 hospitals and 47,100 clinics. Eligible adults had a body mass index of 30 or higher, or 27 or higher with at least one obesity-related comorbidity; patients with type 2 diabetes or without a recorded BMI were excluded. New initiators were tracked from December 22, 2025, to March 15, 2026, with new initiation defined as a first prescription with no same-drug prescription in the prior 12 months.
Among the 47,894,786 eligible adults (mean age 52.4 years; 57.7% female), 148,792 initiated oral semaglutide, compared with 227,040 for injectable semaglutide and 355,513 for tirzepatide. Most oral semaglutide initiators (87.6%) received the oral Wegovy formulation, while 12.4% received Rybelsus, the older oral semaglutide product approved for type 2 diabetes since 2019. Weekly initiation of oral semaglutide climbed from near zero to a peak of 4.56 per 10,000 eligible adults (95% CI, 4.50–4.62) in week 10, corresponding to March 2–8, 2026.
Prior GLP-1 use patterns suggest the oral formulation is drawing both new patients and switchers. According to the research letter, 53.0% of oral semaglutide initiators had no GLP-1 receptor agonist use in the prior 12 months, while the most common prior exposures were injectable semaglutide (28.9%) and injectable tirzepatide (27.5%). The authors said this suggests early uptake reflected “both expansion to new users and switching from existing GLP-1 RA therapies.”
Key Numbers at a Glance
| Metric | Value |
|---|---|
| Eligible adults in cohort | 47,894,786 |
| Oral semaglutide initiators (Dec 22, 2025–Mar 15, 2026) | 148,792 |
| Injectable semaglutide initiators | 227,040 |
| Tirzepatide initiators | 355,513 |
| Peak weekly oral semaglutide initiation (week 10) | 4.56 per 10,000 (95% CI, 4.50–4.62) |
| Oral semaglutide initiators with no prior GLP-1 RA use | 53.0% |
| Prior injectable semaglutide exposure | 28.9% |
| Prior injectable tirzepatide exposure | 27.5% |
| Oral Wegovy share of oral semaglutide initiations | 87.6% |
| Rybelsus share of oral semaglutide initiations | 12.4% |
Why This Matters for Peptide Therapy and Research Peptide Businesses
The rapid uptake of an oral GLP-1 receptor agonist carries direct implications for peptide therapy clinics, telehealth platforms, and research peptide suppliers. For clinics, the data suggest that patient demand is shifting toward oral options that may lower barriers associated with injectable therapies — a point the researchers themselves noted when discussing the potential impact of additional oral options such as orforglipron, approved in April 2026. Industry observers note that this shift could affect inventory decisions, consultation workflows, and the mix of services clinics offer, though the Epic Cosmos analysis did not measure clinic-level economics or patient outcomes.
For research peptide businesses, the findings underscore the importance of distinguishing between FDA-approved GLP-1 receptor agonists and research-use-only peptides. Oral semaglutide is an approved medicine with a defined indication, labeling, and prescription requirement; research peptides are supplied for laboratory use and are not authorized for human administration. As demand for GLP-1-related products grows, suppliers may face increased scrutiny of quality documentation, batch traceability, and claims. Peptide purity, as measured by HPLC, does not by itself establish safety, sterility, or clinical efficacy, and a certificate of analysis does not guarantee suitability for human use.
The supply chain implications extend to API sourcing and finished-product manufacturing. Semaglutide is a synthetic peptide produced through solid-phase peptide synthesis or hybrid approaches, and the global supply of GLP-1 APIs has been under pressure as demand for obesity medications has risen. The Epic Cosmos data do not quantify API demand, but the initiation volumes — nearly 149,000 oral semaglutide starts in under three months — illustrate the scale at which approved GLP-1 therapies are being adopted. For stakeholders tracking peptide supply, this news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
Research and Market Context
The FDA approval of oral semaglutide 25 mg for weight management was based on the OASIS trial program and the SELECT trial (NCT03574597), according to Novo Nordisk. In the 64-week OASIS 4 trial (NCT05564117) of 307 adults with obesity or overweight and at least one comorbidity, participants who adhered to treatment lost a mean 16.6% of body weight, and one in three lost 20% or more. Novo Nordisk described the weight loss as similar to injectable semaglutide 2.4 mg. These are clinical trial results from a specific population under study conditions; they do not establish outcomes in routine practice, and the Epic Cosmos analysis did not evaluate weight-loss outcomes.
The demographic profile of oral semaglutide initiators differed from those starting injectable semaglutide or tirzepatide. Oral semaglutide initiators were older (mean age 53.3 vs 49.7 and 50.5 years), more often female (72.7% vs 70.0% and 67.1%), had a lower mean BMI (36.6 vs 37.6 and 38.0), and were more often covered by Medicare (13.4% vs 9.3% and 10.2%). Family medicine clinicians wrote about half of the initiating prescriptions for each drug. These descriptive differences may reflect prescribing patterns, coverage, or patient preferences, but the study was not designed to test causal explanations.
Tirzepatide’s continued lead in weekly initiations may reflect its greater weight-loss efficacy and established clinical use, the researchers suggested. That is a hypothesis, not a finding tested in this analysis. The study also could not capture prescriptions written outside participating Epic health systems, such as online and direct-to-consumer platforms, and the analysis was descriptive without adjustment for confounding. Prescribing indications were unavailable, and prescription orders may not reflect dispensing or actual use.
What Comes Next
The authors called for longer-term studies of persistence, adherence, and clinical outcomes with oral GLP-1 receptor agonists in routine practice. For the peptide industry, key questions include whether oral GLP-1 uptake continues to accelerate, how payers and clinics adjust formularies and workflows, and whether supply chains for semaglutide API and finished oral formulations can keep pace. PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates.
Clinics and telehealth operators evaluating GLP-1 service lines should verify product authenticity, prescribing requirements, and regulatory status for each specific drug product. Research peptide suppliers should maintain clear documentation distinguishing research-use materials from approved medicines. The available evidence does not yet establish how oral GLP-1 adoption will affect compounded peptide demand, clinic revenue, or long-term patient outcomes; those questions will depend on further data and on how regulators, payers, and manufacturers respond.
Frequently Asked Questions
What did the JAMA Network Open study find about oral semaglutide uptake?
The study found that weekly initiation of oral semaglutide among eligible US adults rose from near zero to a peak of 4.56 per 10,000 eligible adults in week 10 after its December 22, 2025 approval, briefly exceeding injectable semaglutide but remaining below tirzepatide throughout the study period.
Is oral semaglutide the same as research peptides?
No. Oral semaglutide 25 mg (Wegovy) is an FDA-approved prescription medicine for weight management in eligible patients. Research peptides are supplied for laboratory research use only and are not approved for human administration. They should not be treated as interchangeable.
What are the study’s main limitations?
The analysis was descriptive and did not adjust for confounding. Prescribing indications were unavailable, orders may not reflect dispensing or use, prescriptions outside participating Epic health systems (such as online and direct-to-consumer platforms) may be missed, and data delays may limit capture of early uptake.
How might this affect peptide therapy clinics?
The data suggest growing patient interest in oral GLP-1 options, which may influence clinic service design, inventory, and consultation workflows. However, the study did not measure clinic economics or patient outcomes, so the operational impact remains uncertain and will depend on payer coverage, prescribing practices, and supply availability.
Comments